Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 200 clinical trials
A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy (CUPISCO)

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum based induction chemotherapy.

  • 158 views
  • 27 Oct, 2022
  • 116 locations
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of SAR408701 Used in Combination With Ramucirumab in Metastatic, Non-squamous, Non-small-cell Lung Cancer (NSQ NSCLC) Patients With CEACAM5-positive Tumors, Previously Treated With Platinum-based Chemotherapy and an Immune Checkpoint Inhibitor (CARMEN-LC04)

Primary Objectives: Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Part 2: To assess the antitumor activity of SAR408701 in combination with ramucirumab in the NSQ NSCLC population. Secondary Objectives: To assess the …

platinum-based chemotherapy
cancer
squamous non-small cell lung cancer
measurable disease
  • 4 views
  • 23 Oct, 2022
  • 13 locations
Randomized, Open Label Phase 3 Study of SAR408701 Versus Docetaxel in Previously Treated Metastatic Non- Squamous Non-Small Cell Lung Cancer Patients With CEACAM5 Positive Tumors (CARMEN-LC03)

with standard-of-care platinum-based chemotherapy and an immune checkpoint inhibitor (ICI). The primary objective is to determine whether tusamitamab ravtansine improves the overall survival

squamous non-small cell lung cancer
docetaxel
platinum-based chemotherapy
cancer
measurable disease
  • 60 views
  • 27 Oct, 2022
  • 192 locations
Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study

PROTOCOL SYNOPSIS Clinical Protocol ESR-20-20907 Study Title: Durvalumab (MEDI4736) plus platinum-based chemotherapy in advanced large-cell neuroendocrine tumors of lung (LCNEC): a pilot phase

  • 0 views
  • 15 Mar, 2022
  • 1 location
Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

The aim of the study was to investigate the safety and efficacy of Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell

  • 1 views
  • 25 Mar, 2022
  • 1 location
Durvalumab in Combination With Chemotherapy in Virus-infected Patients With Non-small Cell Lung Cancer

This is a phase II trial of durvalumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection

neutrophil count
pemetrexed
serum bilirubin level
platelet count
platinum-based chemotherapy
  • 0 views
  • 03 Jul, 2022
  • 3 locations
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC (ADIVO Lung)

with or without CTLA4 inhibitors) and platinum-based chemotherapy. The study medications include nivolumab, an anti-PD1 inhibitor and ADG106, an agonist antibody of 4-1-BB. The investigators

  • 0 views
  • 14 Apr, 2022
  • 1 location
  • 0 views
  • 27 Jan, 2021
  • 2 locations
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

A Phase 2, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Lorlatinib Monotherapy in Crizotinib and Platinum-based Chemotherapy Treated Locally Advanced or

  • 0 views
  • 15 Jun, 2022
  • 1 location
MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (MITO 35a)

cancer BRCA wild type, in partial or complete response to first line platinum-based chemotherapy, receive Olaparib maintenance therapy (300 mg, tablets formulation twice daily).

  • 0 views
  • 10 Mar, 2022
  • 1 location